Under the agreement, iNovacia will provide small molecule lead generation services and use its proprietary screening library to identify modulators of pharmaceutical targets of interest to Agios Pharmaceuticals. Financial terms of the agreement are not disclosed.
Dr. Thomas Olin, CEO of iNovacia comments the collaboration: “We have had successful screening projects with Agios in the past and we are now proud to be able to extend this relationship. We are pleased that Agios and other US and European companies continue to appreciate the value of our premium screening operations and proprietary screening library as a mean to generate high quality chemistry starting points”.
iNovacia provides high-throughput screening (HTS), fragment-based screening (FBS) and other drug discovery services to translate targets into validated leads for pharmaceutical and biotech companies. Enabled by a proprietary 300,000 compound library of highest international standard, unique biophysical tools for characterization of mode-of-action and structure-activity relationships, iNovacia mitigates technical risk, minimizes lead-time and optimizes quality of drug discovery projects. iNovacia is a wholly owned subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN).